Dextech Medical AB (XSAT:DEX)

Sweden flag Sweden · Delayed Price · Currency is SEK
7.50
+0.30 (4.17%)
At close: Oct 15, 2025
4.17%
Market Cap138.64M
Revenue (ttm)3.22M
Net Income (ttm)-4.84M
Shares Out18.49M
EPS (ttm)-0.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume641
Average Volume10,053
Open7.50
Previous Close7.20
Day's Range7.50 - 7.50
52-Week Range3.62 - 11.00
Beta1.27
RSI39.22
Earnings DateNov 3, 2025

About Dextech Medical AB

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2004
Employees 1
Stock Exchange Spotlight Stock Market
Ticker Symbol DEX
Full Company Profile

Financial Performance

In 2025, Dextech Medical AB's revenue was 3.22 million, a decrease of -40.15% compared to the previous year's 5.39 million. Losses were -4.84 million, 2.96% more than in 2024.

Financial Statements

News

There is no news available yet.